A radioiodinated linear vasopressin antagonist: A ligand with high affinity and specificity for V1a receptors  by Schmidt, A. et al.
1. INTRODUCTION 
Receptors for vasopressin and oxytocin have now 
been characterized in a large number of tissues and cell 
types using different radiolabelled ligands (see Table I). 
Many of these studies, in particular the autoradio- 
graphical analysis of receptor distribution in hetero- 
geneous tissues like brain and kidney, have been 
hampered by the low specific radioactivity and the lack 
of specificity of these ligands which do not discriminate 
efficiently between the vasopressin and the oxytocin 
receptors. Radioiodinated vasopressin and oxytocin 
analogues of high specific radioactivity and good sclec- 
tivity are very valuable toois for studying this distribu- 
tion. We have recently developed an oxytocin anta- 
gonist (ligand 8, Table I) which has a very good affinity 
and a very good selectivity for oxytocin receptors [5]. 
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Abbreviations: Phaa, Phenylacetyl (C~HS-CHzCO-); D-Tyr-Et), O- 
ethyl D-tyrosine; D-Tyr(Me), O-methyl D-tyrosine; (Linear AVP AR- 
tag) is used to denote the AVP linear VI, antagonist having the 
followinp structure: 
1 2 3456789 
Phaa-D-Tyr(Me)-Phe-Gin-Asn-Arg-Pro-Arg-Tyr-NH2, 
Its tnonoiodo and radioiodinatcd erivatives are designated by: ([I]- 
Linear AVP Antag) and by ([‘?]-Linear AVP Antag), respectively. 
AVP, arginine vasopr&sid; OVT, ornithine vasutarin; OT, oxytocir 
d(CH2)5[Tyr(Me)2,Thr4.Thy4,Tyr-NHz’]OVT, [I-(p-mercapto-p.p- 
cyclopentamethylcnepropionic acid), 2-0-methyltyrosine, 4-threo- 
nine, 8-ornithine.9.tyrosylamidelvasotocin 
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Highly selective ligands for the three subtypes of 
vasopressin receptors Vln, Vlb and VZ having a high 
specific radioactivity and a good affinity are still 
awaited. We have previously prepared aradioiodinated 
vasopressin antagonist (ligand 9, Table I). This ligand 
labelled the VI, hepatic vasopressin receptors with a 
high affinity (0.28 nM). However, it does not 
discriminate between vasopressin and oxytocin recep- 
tors, and it shows a high nonspecific binding in 
autoradiographical studies [B]. A VI-vasopressin recep- 
tor antagonist (ligand 10, table I) has been prepared and 
radioiodinated by Kelly et al. [4] and Gerstberger and 
Fahrenholz [7], It has an affinity of 3.0 nM for the rat 
liver vasopressin receptor. Unfortunately, its affinity 
for the oxytocin receptor has not been estimated, and 
although this ligand may be useful for 
autoradiographical studies in the kidney, the very high 
non-specific binding observed in the brain studies [7,8] 
makes its use in the brain difficult. 
We recently reported some pharmacological proper- 
ties of a series of 8 linear VI, antagonists containing 
Tyr-NH2, designed as potential radioiodinated ligands 
[9,IO]. These were designed by incorporating a C- 
terminal Tyr-NH2 at position nine in analogues of the 
potent and selective linear octapeptide VI, antagonist: 
1 2 345678 
Phaa-D-Tyr(Et)-Phe-Gin-Asn-Lys-Pro-&g-NH2 [1 l] 
having modifications at positions 1, 2 and 6, to give a 
series of eight Tyr-NHa” analogues [9,IO] (Phaa = 
Phenylacetyl). The most potent VI, antagonist of this 
series had a D-Tyr(Me)2 and an Arg6 in place of D- 
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Tyr(Ec)’ and Lys’, respectively. It has the following 
structure: 
Phaa-D-Tyr(Me)-Phe-GIn-Asn-Arg-Pro-Arg-Tye- 
NH2 (Linear AVP Ancag) [9,10]. 
In preliminary iodination studies the monoiodinated 
derivative of this peptide, i.e. [iZSI]-linear AVP Antag 
was also found to retain high affinity for VIM receptors. 
It was thus selected for the studies reported here. We 
now describe the synthesis, radioiodination and estima- 
tion of the activities of this linear vasopressin an- 
tagonist ([‘2sI]-Linear AVP Antag) which contains no 
sulfhydryl groups. It. has a very high affinity for 
vasopressin receptors, a good selectivity for the VI, 
receptor and a high specific radioactivity. Preliminary 
autoradiographic studies show good specific labelling 
with low non-specific binding in areas known to contain 
vasopressin receptors. 
2. MATERIALS AND METHODS 
2. I. Synthesis of Phaa-D-Tyr(Me)-Phe-Gln-Asn-Arg-Pro-A@-Tyr- 
PJHz (Linear A VP Antag)’ 
The protected precursor required for the synthesis of Phaa-D- 
Tyr(Me)-Phe-Gin-Asn-Arg-Pro-Arg-Tyr-NH2 was synthesized by the 
manual sotid-phase method [I21 starting from Boc-Tyr(Bzl) resin 
following previously described procedures [ 11,131. Successive cycles 
of dcprorcerion, ncutralirnlion and coupling gnvc the prolceted aeyl 
octnpcptide resin, Ammonolyris in methanol [I I, I3] yielded crude 
Plraa-D-TyrCMc)-Phc-Gln-Asn-Arg(Tos)-Pro-Arg(Tor)-Tyr(Bzt)- 
NH2 (A), which was purified by precipirarion from dimerhylfor- 
mamide/water; yield 76%, rn.p. 190-194°C. [&I” ~26.3~ (e 111 I, 
DMF), Thin layer chromatography in three different systems showed 
that this maWal was pure: RI+‘+) m 0.54, RF(B) = 0.55, RF(C) = 
034 (A = butanol/acctic acidEwatcr, 4: I: I; B = bwwol/acctic 
acid/waIer, 4: I :5 (upper phnre); C = chloroform/merhanol, 4:l). An 
aliquot of the protected precursor (A) (1 IO mg) was rcduccd with 
Na/liquid NH) [ 141 and the crude pcptide was purified in a two-slcp 
procedure involving gel filtration on Sephadcx G-15 in 5OQ accfic 
acid. and on Sephadex U-I-20 in 2 N acetic ncid ns previously dencrib- 
cd [l I ,13,15]. The final lyophiliaation gave the desired product Phaa- 
D-Tyr(Mc)-Phc.Gln-Am-Arg-Pro-Arg-Tyr-NH2 (linear AVP Anlag) 
as a white powder, 74 mg (88% yield); [aJo” = -49O (c n 0. I, 50% 
AcOH), &(A) = 0.22. RF(B) = 0.21, RI(D) = 0.40 (D = 
butanol/aceric ncid/watcr, 2: 1: I). Amino acid analysis: ASQ 1,OS; 
Glu I ,03; Pro I .02; Tyr 1.85; Phc 1.04; Arg 2.03; NH3 3.1. The 
homogeneity of the product was additionally confirmed by HPLC. 
Some pharmacological properties for this peptide (Linear AVP An- 
tag) [9,10] and its monoiodo derivative ([II-Linear AVP Antag) are 
given in Table II. 
2.2. Chloramine-T iodination 
The AVP VI, antagonist (Linear AVP Antag) was iodinated on the 
9.tyrosylamide by means of the oxidant chloramine-T (Merck, Ger- 
many) as previously described [6], The unlabelled monoiodinated an- 
tagonist ([II-Linear AVP Antag) was prepared by ICI iodination [S]. 
It was used to identify the [‘ZSI]-Linear AVP Antag on HPLC and to 
establish inhibition constants for AVP and OT receptors (Tables 1 and 
II). 
Table II 
Biological activities of Linear AVP Antagonist and [II-Linear AVP Antagonist 
Peptide Anti-vasopressor pAzc Antidiuretic U/mg 
Linear AVP Antagonist”lb 8.94*0.03 0.042~0.008 
[II-Linear AVP Antagonist 8.7OztO.03 0.034~0.004 
- 
“This has the following structure: Phaa-D.Tyr(Me)-Phe-Gin-Asn-Arg-Pro-Arg-Tyr-NIiz 
“Data from references [9,10] 
‘Antagonistic properties represent pA2 values r SE, pA2 is the negative log. of AZ which is the estimated concentration of antagonist reducing the 
response to 2 x units of agonist to equal the response to 1 x unit administered before the antagonist 
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drtrsribed b>+ Ncvtlle up IB r~ep I I 17) and xforetl in liquid nitrogen un* 
lit use. Rat kidney menrbranen were prcpnrcd 8~ desertlard by Butlcn 
el al. [it%]. Ea~rogcntrcd PIII u18rus membrnncs were prepared as 
described by Ehwlr et al, [I’>), Rwt an~eri~ phicwy membranes were 
preprrcd UI described by Gaillard et aI, [2(l), 
hlcmbrone% (2 II& far liver, 80 pfj for kidney, 2 jr@ for ulcrus and 56 
11p far ndenohypophyrin) were incubelrd in %I mM TritiHCl (pH 7.41, 
5 mM MgC$, I mp/ml LISA and varying concentrations of tnbellcd 
and unlrbelled peptides. lncubnrion a~ WC Irswd I’or 20 min ([“HI. 
AVP, ndenohypo~hyais), 30 min ([‘H).AVP, kidney), 40 min ([?I- 
d(C&)r[Tyr(Me) ,Thr”,Tyr.NHa*]OVT, uterus) or 45 min ([‘srll- 
Linear AVP Antag, liver). Non.specific bindiny was dctermincd in 
rhe presence of a 2SWol~l CWCXII of unlabcllcd pqxidc. Bound and 
free rndioartiviry were separated by filtrnlion either over Milliperc 
(RAWP, I .2 rrm) Oil&s for the tritiatcd pepride or over Whatman 
GPX filrcrs, presoaked in I(3 mg/ml BSA (for at least 2 h) for rhe 
radioiadinated pcptidcs, as described [21], Inhibition eonstnnts for 
the non.labclled analoguea wcrc determined in comperirion cs- 
pcrirrrenre in rhe presence of 0.06 nM (‘l’I]-Linenr AVP Antag (liver); 
I-l .3 nM [“HI-AVP (kidney); 5.9 nM (‘H].AVP (nderrotiypophysis), 
0.06 nM [‘“‘I]-cl(CHr)rr[Tyr(MC)1,ThpJ,Tyr”Nti~’]GVT (uterus). 
Brain slicer; from adult female Wislar rats were prepared as describ- 
ed by Elands et al, [S] 1 They were prc-incubnted at room temperature 
for I5 min in 50 mM Tris-HCI. pH 7.4, containing 0. I% BSA. In- 
cubation was carried OUI for 1 h al room tempcraturc in a humid 
chamber by covering each section with 400~1 incubation medium (SO 
mM TriseHCI pH 7.4, 5 mM MgCIl, 0.1 mM bacitracin and 0.1% 
BSA) containing 0.06 nM [‘2”lj-Linear AVP Antag atone or in the 
prcscnce of 0,l FM AVP, or 0.05 nM [‘q]” 
d(CW&[Tyr(Me)‘,Thr’,Tyr-NH:‘]C?VT alone or in the presence of 
0, I pM OT, The slides were dried wirh cold air and then placed in an 
X-ray cassette in contact with hypcrfilm Bctamax (Amcrsham) for 4 
days (antagonist AVP) or 7 days (antagonist OT), 
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pearlezf to bd: a highly potent ~nciv~~~pre~~or popridc 
with w pA;1 value in viva oP8.94 (T&e IE), ft hm a weak 
rntidiurctis wctivity, ladinatian ST the %tyreaylamida 
residue reduced the antivwroprc%ror p tency about 43% 
and did not ehtlnge antldiuretie aetiviry ~ignifieanrly. 
The icldinared vessprenain antngonisc inhibited E?]- 
Lincnr AVP Anrgg binding to Vlr (liver), [$I]-AVP 
binding to Vlb (wdcnehypophysis) and VY (kidney) 
varepreuin rceeprers and [‘““I]-ct(CHa)t- 
[~yr(Nc)f,“Plrr”,“Pyp-NHI’JOV*P binding to axytocin 
receptim from the WXUJ of an estrogenizcd rat. In line 
with in vive data, it has a very high affinity for VI, 
reeeptsr (Table 111). It has also a fairly high but 
significantly lower affinity for 0T receptors and a very 
low affinity for VIM and Va receptors, Hill plot slopes 
did not differ nignificantly from unity, indicating an in- 
teraction with single populations of receptor sites in all 
CIOCS. 
3.2.. [“‘I]-Littear A VP An&g bindhg 
Specific [‘Z’I]-Lincor AVP Antag binding to rat liver 
membranes was a fairly slow process. At 3;)OC and for 
0.1 nM ligand, a concentration close to the equilibrium 
dissociation constant, a maximum binding was reached 
within 30 min, The estimated haif-time was about 4 min 
30 s. All Further experiments were performed at 30°C 
and the duration of membrane incubation in the 
presence of [‘251]-Linear AVP Ancag was 45 min. 
Specifically bound [*2SI]-Linear AVP Antag could be 
partially released in a rime-dependent manner by ad- 
ding an excess OF unlabelled [I].Linear AVP Antag. 
50% of the specifically bound radioactivity was releas- 
ed after 60 min incubation in the presence of unlabellcd 
[II-Linear AVP Antag. 
Fig, 1 shows a typical Scatchard analysis of [“‘I]- 
Linear AVP Antag binding to liver membranes. The 
high specific radioactivity of [“‘I]-Linear AVP Antag 
allowed a precise saturation binding analysis to be done 
with only 2 yg of membrane protein per assay. 
Table III 
Affinities of [I]-Linear AVP Antagonist 
Inhibition constants of the [II-Linear AVP Antag were determined in competition experiments. Liver, adenohypophysis, kidney medulla and uterus 
membranes were incubated with 0.06 nM [“‘I]-Linear AVP Antag for liver vasopressin receptor, 1.2-5.9 nM [‘W]AVP for adenohypophysis and 
kidney vasopressin receptors, 0.05-0.06 nM [lZSl]-d(CH& [Tyr(Me)*,ThrJ,Tyr-NHz’]OVT for uterus oxytocin receptors and varying concentra- 
tions of [II-Linear AVP Antag. Values were obtained in independent experiments, each performed in triplicate 
Peptide Inhibition constants (nG) 
Liver’ Adenohypophysis’ Kidney’ Uterus3 
[I]-Linear AVP Antag 0.18 92 62 1 A 
0.17 33 2.8 
‘Competition experiments with [1251]-Linear AVP Antag 
*Competition experiments with [%l]AVP 
%ompetition experiments with [‘251]-d(CW~)s[Tyr(Me)Z,Thr4,Tyr-Nl-l~’]OVT 
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Fig, I, Concentration.dependence of [~=~i].Ltnear AVP Antail bin- 
din8 (0,03=0.90 nM) to a Liver membrane preparation, The values 
represented in tile graph are From one experiment. The protein con- 
tent per tube was 2/=g, the correlation coefficient of linear egression 
w~s 0,96, "The dissociation constanl was 0.060 nM and the maximal 
binding capacity ?50 final/rag protein, 
The dose-dependent specil'ie [tZ~ll-Linear AVP An- 
tag btndlnj a~ equilibrium to rat liver membrane 
preparations revealed bindinll to one class of receptor 
sites with a very high affinity (K,s - 0.06 aM. results 
obtained from 2 separate experiments in triplicate) and 
a high capacity (Bm,~ - 750 final/roB protein). There 
was a 8ood correspondence in affinity constams 
calculated for i l l-Linear AVP Anta8 from competition 
experiments on [t=Sll-Linear AVP Anta i  binding to 
liver vasopresstn receptors (Table Il l) and the affinity 
constants calculated from tile concentration- 
dependence analyses (Fig. 1), 
At a [~zsl].Ltnear AVP Antag concentration close to 
the K,, value (0,06 aM), the non-specific binding was 
18,7%, 
[~HI.AVP binding to Vtb- and V2-receptor sites was 
inhibited with a very low potency (respectively Kq = 92 
nM and Ki = 47 nM) (Table I11). The Vta-receptor/Vtb- 
receptor and the VLa-receptor/Va-receptor selectivity 
index (the calcalated ratio of  Kts of  one ligand for two 
different receptor types) were respectively, 0,0018 and 
0.0036. [12SlI.d(CHz)~[Tyr(Me)2,Thr4,Tyr-NHzglO~CT 
binding to aT-receptor  sites was also inhibited with a 
low potency (Ki = 2.1 nM) (Table II1), The V~a- 
/ r 
tCG 
Fig. 2. Autoradiographs of female rat brains. Autoradiographs were obtained from coronal sections incubated with 0.06 nM [~251]-Linear AVP 
Antag (A,B) exposed for 4 days or with 0.05 nM [t~5I].d(CHz)s[Tyr(Me)2,Thr4,Tyr-NH29]OVT (C,D) exposed for 7 days, The non-specific binding 
(left part of the sections) was obtained by incubating the slices in the presence of 0,1 t~M AVP for vasopressin antagonist or 0. I ~.M aT  for o×ytocin 
antagonist, Calibration: 2 raM, 
Abbreviations: CG, central grey; CPu, caudate-putamen; DG, dentate gyrus; ICj, islands of Calleja, LSD, Laterial septum nucleus {dorsal); LSI, 
lateral septum nucleus {intermediate); S, subiculum; SC, superior cotliculus; SN, substantia nigra, 
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part of the enudate-putamen and the islands of Callejn 
(Fig, 261, while intense labclliny was: detected in the 
subiculum (Fig, X3), 
Thus, the radioiadinated liynnd ([‘f’I)-Pha~-D- 
Tyr(Me).Phe-eln-Asn-Arg-PrQ-hrg-Tyr-Nap ([““I)- 
Linear AVP Anrap) appears a good ligand for VI* 
vasoprcsain receptors. It is worth noting thar irr; affinity 
for VI, rcceptorr (&I = Q,O6 nM) is much higher than 
any radiolabellcd ligand developed so Far for 
vasoprcssin rcccytors. Moreover, its high sclcctivity and 
high specific radioactivity make this lieand a very good 
tool for future stud& on vasopressin receptor locnliza- 
tion and characterimtion. 
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